IVVD
IVVD clinical trials: Invivyd, Inc.
Every trial on ClinicalTrials.gov where Invivyd, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IVVD on the catalyst calendar · IVVD registry changes
- Primary completion Jun 2027Sponsor estimatePhase 2NCT07899346Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromeInvivyd, Inc. · Long COVIDNot yet recruitingIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2026ActualPhase 3NCT07655180Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineInvivyd, Inc. · COVID-19CompletedIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2026Sponsor estimatePhase 3NCT07298434Study of VYD2311 for the Prevention of COVID-19Invivyd, Inc. · COVID-19Active, not recruitingIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2024ActualPhase 3NCT06039449A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older...Invivyd, Inc. · COVID-19CompletedIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2025Sponsor estimatePhase 1NCT06523153A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy ParticipantsInvivyd, Inc. · COVID-19Active, not recruitingIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 4, 2022ActualPhase 2/Phase 3NCT04859517Evaluation of ADG20 for the Prevention of COVID-19Invivyd, Inc. · COVID-19TerminatedIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06004128Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to...Invivyd, Inc. · COVID-19No longer availableIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2024ActualPhase 1NCT05791318A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult ParticipantsInvivyd, Inc. · COVID-19CompletedIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2022ActualPhase 2/Phase 3NCT04805671Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19Invivyd, Inc. · COVID-19TerminatedIVVDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner